Mabwell(SH:688062)2026-02-27 08:55Financial Performance - Total revenue for 2025 reached RMB 66,251.56 million, a significant increase of 231.62% compared to RMB 19,978.16 million in the previous year[3] - The company's net profit attributable to shareholders was RMB -97,017.55 million, showing a decrease from RMB -104,391.92 million year-on-year[3] - The basic earnings per share were RMB -2.43, slightly improved from RMB -2.61 in the previous year[3] - The weighted average return on net assets dropped by 48.77 percentage points to -99.05% compared to -50.28% in the previous year[3] Assets and Equity - The total assets at the end of the reporting period were RMB 456,784.79 million, reflecting a 6.84% increase from RMB 427,550.89 million at the beginning of the period[3] - The equity attributable to shareholders decreased by 77.78% to RMB 34,866.59 million from RMB 156,887.74 million[3] Revenue Drivers - The increase in total revenue was primarily due to significant income from licensing agreements with Qilu Pharmaceutical Co., Ltd. and DISC MEDICINE, INC., along with increased drug sales[5] R&D and Investment - The company maintained high levels of R&D investment as multiple innovative drugs are in critical trial phases, impacting overall financial performance[6] - The decrease in equity and net asset value was attributed to substantial investments in new drug development and increased operating costs due to commercialization efforts[6] Investment Risks - There are no significant uncertainties affecting the accuracy of the financial report, but investors are advised to be cautious regarding investment risks[7]